Episode 13: Radiation for Prostate Cancer with Dr. Andrew Loblaw (Part 2)

https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/d2/9a/09/d29a09bb-6bb4-d3b6-1911-aad1979f4b90/mza_8029225495197491321.jpg/600x600bb.jpg

The View on GU | with Lalani and Wallis

Dr. Aly-Khan Lalani & Dr. Christopher Wallis

33 episodes

1 week ago

There is currently a lack of organic multi-disciplinary discussion on what is truly impactful to the field of genitourinary (GU) cancers. The View on GU with Lalani and Wallis is a podcast that will integrate key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians. Importantly, Lalani and Wallis will also discuss the impact of governmental approvals and funding considerations on the GU oncology treatment landscape and provide practical considerations on the management of patients on new-to-market therapies.

Medicine

Health & Fitness

RSS

All content for The View on GU | with Lalani and Wallis is the property of Dr. Aly-Khan Lalani & Dr. Christopher Wallis and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/40427888/41d07e9c28fc00dc.jpeg

Episode 13: Radiation for Prostate Cancer with Dr. Andrew Loblaw (Part 2)

The View on GU | with Lalani and Wallis

19 minutes 33 seconds

1 year ago

Episode 13: Radiation for Prostate Cancer with Dr. Andrew Loblaw (Part 2)

Building on Episode 12, which focused on primary treatment for prostate cancer, Drs. Loblaw, Lalani and Wallis move on to discuss post-op treatments, including the evolution of post-operative radiotherapy and the shift from adjuvant therapy to early salvage therapy.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com

This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, Novartis, Pfizer and TerSera